Analysts Offer Predictions for DNLI Q2 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at William Blair issued their Q2 2025 EPS estimates for Denali Therapeutics in a research note issued to investors on Monday, July 7th. William Blair analyst M. Minter forecasts that the company will earn ($0.80) per share for the quarter. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics' Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($2.93) EPS and FY2028 earnings at ($0.56) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the previous year, the business earned ($0.68) EPS.

Several other analysts have also recently issued reports on DNLI. Wedbush cut their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Robert W. Baird cut their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Bank of America cut their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a report on Monday, May 19th. HC Wainwright dropped their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $33.71.

Denali Therapeutics Price Performance

DNLI opened at $14.33 on Wednesday. The stock has a market capitalization of $2.08 billion, a PE ratio of -5.37 and a beta of 1.33. The firm's fifty day moving average price is $14.34 and its 200 day moving average price is $16.69. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33.

Institutional Trading of Denali Therapeutics

A number of large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its stake in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after buying an additional 1,551 shares during the period. Sterling Capital Management LLC lifted its position in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Denali Therapeutics in the first quarter worth approximately $41,000. GF Fund Management CO. LTD. purchased a new stake in shares of Denali Therapeutics in the fourth quarter worth approximately $62,000. Finally, Point72 Hong Kong Ltd bought a new position in Denali Therapeutics during the fourth quarter valued at approximately $65,000. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.